Table 4 |
|||||||||||
|
Proportion of children with 8-fold increase of anti-MSP3 antibodies at day 84 by vaccine type |
|||||||||||
|
Antibody |
15 μg MSP3 |
30 μg MSP3 |
Engerix B |
||||||||
|
|
|||||||||||
|
N |
n |
% |
N |
n |
% |
N |
n |
% |
|||
|
|
|||||||||||
|
Total IgG |
15 |
4 |
26.7 |
12 |
4 |
33.3 |
13 |
1 |
7.7 |
||
|
IgG1 |
15 |
15 |
100 |
12 |
10 |
83.3 |
13 |
2 |
15.4 |
||
|
IgG2 |
15 |
0 |
0 |
12 |
0 |
0 |
13 |
0 |
0 |
||
|
IgG3 |
15 |
13 |
86.7 |
12 |
11 |
91.7 |
13 |
6 |
46.2 |
||
|
IgG4 |
15 |
3 |
20 |
12 |
4 |
33.3 |
13 |
1 |
7.7 |
||
|
|
|||||||||||
|
N = total vaccinated, n = responders |
|||||||||||
|
Lusingu et al. Malaria Journal 2009 8:163 doi:10.1186/1475-2875-8-163 |
|||||||||||
